Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics' Q1 Fall 30 Percent

NEW YORK (GenomeWeb News) – Interleukin Genetics reported yesterday that its first-quarter revenues declined 30 percent and its net loss rose 32 percent, as its consumer product sales and contract research revenue fell.

The Waltham, Mass.-based genetic test maker brought in total revenues of $1.9 million, down from $2.7 million. Its consumer products sales fell to $1.5 million from $2 million year over year, while its contract research revenues were $203,687 versus $537,013 the year before. The firm's genetic testing service revenue increased to $137,511 from $101,752.

Interleukin's net loss grew to $2.5 million, or $.08 per share, from $1.9 million, or $.06 per share.

Its R&D expenses increased to $881,556 from $813,371, while its SG&A spending declined to around $2 million from $2.1 million.

Interleukin finished the quarter with cash and cash equivalents of $1.7 million.

"Looking ahead to the rest of the year, we are preparing to launch our own genetic test brand, and continue to hold discussions with companies regarding partnering opportunities for our various programs, products, intellectual property and genetic biomarker expertise," Interleukin CEO Lewis Bender said in a statement.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.